Summary & Overview
CPT 90677: Pneumococcal Conjugate Vaccine, 20-Valent (PCV20)
CPT code 90677 is a critical billing code for the pneumococcal conjugate vaccine, 20-valent (PCV20), administered intramuscularly. This vaccine offers broad protection against pneumococcal disease, addressing 20 serotypes and representing a significant advancement in preventive immunization. The code is relevant for providers in pediatrics, family medicine, obstetrics & gynecology, infectious disease, and general practice, reflecting its wide clinical applicability.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, cover services billed under CPT code 90677. The publication provides an overview of payer coverage, typical sites of service, and clinical context for PCV20 administration. Readers will gain insight into billing benchmarks, policy updates, and the role of this vaccine in preventive care. The summary also highlights related codes for other pneumococcal vaccines, offering a comparative perspective for providers and billing professionals.
This article is designed to inform healthcare stakeholders about the national landscape for CPT code 90677, including payer coverage, clinical relevance, and billing considerations. It serves as a resource for understanding how PCV20 fits into broader immunization strategies and the evolving standards for pneumococcal disease prevention.
CPT Code Overview
CPT code 90677 represents the administration of the pneumococcal conjugate vaccine, 20-valent (PCV20) for intramuscular use. This vaccine is designed to protect against 20 different serotypes of Streptococcus pneumoniae, a leading cause of pneumonia and other serious infections. The service type is Vaccines, Toxoids, and it is typically provided in an office setting (POS 11). The introduction of PCV20 expands the range of pneumococcal protection available to patients, supporting preventive care efforts in clinical practice.
Clinical & Coding Specifications
Clinical Context
A patient, such as a child or adult, presents to a primary care office (Place of Service 11) for routine immunization. The provider, who may be a pediatrician, family medicine physician, obstetrician/gynecologist, infectious disease physician, or general practitioner, assesses the patient's vaccination history and determines that administration of the pneumococcal conjugate vaccine, 20-valent (PCV20), is indicated. The vaccine is given intramuscularly during the encounter, and documentation reflects the preventive nature of the service. The workflow includes verifying eligibility, obtaining consent, administering the vaccine, and recording the immunization in the patient's medical record.
Coding Specifications
-
Modifiers:
- Modifier
SL: Indicates the vaccine was supplied by the state, typically used when the vaccine is provided at no cost to the provider through a state program. - Modifier
33: Denotes that the service is preventive, used for immunizations and other preventive services.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
208000000X | Pediatrics |
207Q00000X | Family Medicine |
207V00000X | Obstetrics & Gynecology |
207RI0011X | Infectious Disease Physician |
208D00000X | General Practice |
These taxonomies represent the specialties commonly administering the pneumococcal conjugate vaccine.
Related Diagnoses
Z23: Encounter for immunization- Used to indicate that the visit is for the purpose of receiving an immunization. This diagnosis is clinically relevant as it justifies the administration of the pneumococcal conjugate vaccine and is commonly paired with vaccine CPT codes in preventive care encounters.
Related CPT Codes
-
90671: Pneumococcal conjugate vaccine, 15‑valent (PCV15), for intramuscular use- Used as an alternative to
90677when a 15-valent vaccine is indicated instead of the 20-valent. Selection depends on patient age, risk factors, and immunization guidelines.
- Used as an alternative to
-
90732: Pneumococcal polysaccharide vaccine, 23‑valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use- Used in adults or immunosuppressed patients as an alternative or in addition to
90677, depending on clinical recommendations. May be administered sequentially with conjugate vaccines in certain scenarios.
- Used in adults or immunosuppressed patients as an alternative or in addition to
These codes are related as alternatives or adjuncts in pneumococcal immunization workflows. They are not typically billed together unless clinically indicated.
National Reimbursement Benchmarks
National mean rates for CPT code 90677 among commercial payers range from $297.95 for Blue Cross Blue Shield to $326.34 for UnitedHealth Group. The BUCA average (all major commercial payers) is $310.49. Medicare rates are not available in the input, so a direct comparison is not possible.
Rate dispersion varies significantly across payers. Cigna shows the tightest range, with its 25th, 50th, and 75th percentiles all at $308.00, indicating minimal variation. UnitedHealth Group has the widest spread, with a difference of $58.50 between its 75th and 25th percentiles. Blue Cross Blue Shield and Aetna also display moderate dispersion, while BUCA's range is $36.50.
The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.